Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with MASLD and T2DA significantly higher proportion of patients achieved a greater than 30% liver triglyceride reduction as well as MASLD resolution with lanifibranor compared to placeboLanifibranor treatment significantly improved both hepatic and per ...